A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd (2013) Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199–207. https://doi.org/10.1016/j.juro.2013.01.087

Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ (2015) Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med 12(1):248–258. https://doi.org/10.1111/jsm.12731

Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, Burnett AL (2015) Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650–656. https://doi.org/10.1111/bju.13096

Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L (2018) Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology 119:109–114. https://doi.org/10.1016/j.urology.2018.06.003

Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW (2017) Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology 104:102–109. https://doi.org/10.1016/j.urology.2017.01.054

Ralph DJ, Abdel Raheem A, Liu G (2017) Treatment of Peyronie’s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med 14(11):1430–1437. https://doi.org/10.1016/j.jsxm.2017.08.015

Abdel Raheem A, Johnson M, Abdel-Raheem T, Capece M, Ralph D (2017) Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease—a review of the literature and a new modified protocol. Sex Med Rev 5(4):529–535. https://doi.org/10.1016/j.sxmr.2017.07.005

Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG (2017) Impact of number of cycles of collagenase Clostridium Histolyticum on outcomes in patients with Peyronie’s disease. Urology 100:125–130. https://doi.org/10.1016/j.urology.2016.09.050

Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, Ralph OG, Garaffa G, Christopher AN, Ralph DJ (2017) Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int 120(5):717–723. https://doi.org/10.1111/bju.13932

Capece M, Cocci A, Russo G, Cito G, Giubilei G, Cacciamani G, Garaffa G, Falcone M, Timpano M, Tasso G, Sessa F, Campi R, Di Maida F, Cai T, Morelli G, Giammusso B, Verze P, Palmieri A, Ralph D, Mirone V, Mondaini N (2018) Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease: a prospective Italian multicentric study. Andrology 6(4):564–567. https://doi.org/10.1111/andr.12497

Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG (2017) Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med 14(10):1220–1225. https://doi.org/10.1016/j.jsxm.2017.08.008

Carson CC 3rd, Sadeghi-Nejad H, Tursi JP, Smith TM, Kaufman GJ, Gilbert K, Honig SC (2015) Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int 116(5):815–822. https://doi.org/10.1111/bju.13120

Beilan JA, Wallen JJ, Baumgarten AS, Morgan KN, Parker JL, Carrion RE (2018) Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture. Sex Med Rev 6(2):272–278. https://doi.org/10.1016/j.sxmr.2017.07.011

Yang KK, Bennett N (2016) Peyronie’s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology 94:143–147. https://doi.org/10.1016/j.urology.2016.04.049

Masterson TA, Galante A, Butaney M, Pastuszak A, Sadeghi-Nejad H, Ramasamy R (2019) Variation in collagenase Clostridium histolyticum practice patterns: a survey of ISSM members. Int J Impot Res. https://doi.org/10.1038/s41443-019-0126-y

Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, McMahon CG (2017) Changes in the effects of Peyronie’s disease after treatment with collagenase Clostridium histolyticum: male patients and their female partners. Sex Med 5(2):e124–e130. https://doi.org/10.1016/j.esxm.2017.02.001

Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ (2016) Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie’s disease. J Sex Med 13(4):684–689. https://doi.org/10.1016/j.jsxm.2016.02.105

Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A, Ziegelmann M, Trost L, Gelbard M (2019) Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie’s disease: results of a multi-institutional analysis. J Urol. https://doi.org/10.1097/ju.0000000000000032

Masterson T, Patel P, Ramasamy R (2019) Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res. https://doi.org/10.1038/s41443-019-0127-x